PRESS

March 3 2020

EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance 

February 11 2020

EpicentRx opens clinical site at Utah Cancer Specialists for RRx-001 in Small Cell Lung Cancer

December 4 2019

EpicentRx Appoints Senior Life Science Financial Executive Dr. Franck Brinkhaus as Chief Financial Officer

November 25, 2019

EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastoma

November 13, 2019

EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform

November 05, 2019

EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer

June 25, 2019

EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC)

September 17, 2018

Interview – CEOCFO Magazine September 17, 2018 Issue

Q&A with Dr. Corey A. Carter, President and CEO of EpicentRx Inc. developing “smart” oncolytic virus therapies in combining immuno-oncology agents that activate the human immune system against cancer with minimal toxicity for patients